DDW’s Diana Spencer reviews the latest research into fibromyalgia treatment and the new therapies currently in development. With no existing cure for fibromyalgia, a chronic pain syndrome, current treatments focus on managing the symptoms like pain, fatigue and poor sleep, with exercise being a key part of… Read More
Professor Trevor Jones, Co-Chair of the Cannabinoid Research and Development Group (CRDG), discusses how the UK could become a leader in cannabinoid research. The UK is a global leader in biotechnology and one of the top countries for cannabinoid R&D – only Canada and the US publish more cannabinoid research. Read More
Brain disease specialist Aelis Farma has announced results from the clinical Phase IIB trial study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study population, 82% of… Read More
The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report suggests the UK can build on the success of GW Pharmaceuticals, whose multiple sclerosis treatment product… Read More
This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Medicinal cannabis: Why more clinical… Read More
Dr Currien MacDonald, Medical Chair Director at WCG, discusses the challenges and opportunities presented by cannabis research. The recent interest in cannabinoids as potential sources for medicinal use has been a long time coming. Advances in brain science and modern chemistry are supporting a new generation of investigation into cannabinoids,… Read More
This paid-for advertorial by BMG Labtech appeared in DDW Volume 25 – Issue 2, Spring 2024. Cannabinoid research has gained significant attention in recent years, as scientists have been exploring the potential therapeutic benefits of these compounds. From studying their role in treating neurological disorders to pain management, this field of… Read More
Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex. The trial… Read More
In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. What is the regulatory landscape of medical cannabis? Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains… Read More
World pioneer in cannabis research, Professor Raphael Mechoulam, has died in Israel at the age of 92. A professor in the Hebrew University School of Pharmacy, Mechoulam began his cannabinoid experiments in the 1960s in Israel. His research team was the first to isolate… Read More
Listen to this article on the DDW podcast: Michael Sassano, CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. The use of medicinal cannabis across much of the world… Read More
An international study led by McMaster University scientists and published in The British Medical Journal show a minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small. Data from 32 randomised controlled trials showed that… Read More
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW Pharmaceutical’s cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an… Read More
Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to… Read More
Medical cannabis is a growing market in Europe – but there is a lack of the usual regulatory framework intended to harmonise marketing of medicines and keep them safe. Arriello Director of Drug Safety Peter Kohut provides a guide to marketing cannabis products in the diverse European market. Medical cannabis… Read More
